Logo

Noxopharm Collaborates with GenesisCare to Bring Combination Regimen of Veyonda (idronoxil) and Lu-PSMA in Australia

Share this

Noxopharm Collaborates with GenesisCare to Bring Combination Regimen of Veyonda (idronoxil) and Lu-PSMA in Australia

Shots:

  • The collaboration offers a compassionate access program to make the combination therapy of Veyonda & 7Lu-PSMA available to the patients suffering from mCRPC- being treated with theranostics in Australia
  • The combination regimen is currently being evaluated in clinical studies in patients with advanced mCRPC- demonstrating improvement in response rate with mOS (17.1mos.) and a reduction in pain following disease progression
  • Veyonda (bid for 10 days) is a suppository dosage form of idronoxil and inhibitor of S1P and enhances the effect of Lutetium-PSMA (Lu-PSMA) in men with advanced PC

Click here ­to­ read full press release/ article | Ref: Noxopharm | Image: Noxopharm


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions